Erudio Healtherudio.com
Drug
Liposomal irinotecan trials: what clinicians said in public
No HCP commentary report on a trial studying liposomal irinotecan yet. Erudio has found public clinician commentary on 4 clinical trials studying liposomal irinotecan: NAPOLI-1, NCT05382559, NCT07409272 and RASolute 302. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| RASolute 302 NCT06625320 · Revolution Medicines, Inc. DeepView → | previously treated metastatic pancreatic ductal adenocarcinoma | Phase 3 | Deep | View | |||
| NAPOLI-1 NCT01494506 · Merrimack Pharmaceuticals DeepView → | metastatic pancreatic cancer after previous gemcitabine-based therapy | Phase 3 | Deep | View | |||
| NCT05382559 NCT05382559 · Astellas Pharma Inc FocusedView → | KRAS G12D locally advanced or metastatic solid tumors | Phase 1 | Focused | View | |||
| NCT07409272 NCT07409272 · Astellas Pharma Global Development, Inc. FocusedView → | KRAS G12D-mutated metastatic pancreatic adenocarcinoma | Phase 3 | Focused | View | |||